Table 1.
Baseline characteristics in the RA Porto cohort (N = 355).
| Mean ± SD or N (%) | |
|---|---|
| Age, yrs | 58.4 ± 13.1 |
| Male, N (%) | 84 (23.1%) |
| Body mass index, kg/m2 | 26.6 ± 4.5 |
| Medical history, N (%) | |
| Hypertension | 170 (46.8%) |
| Diabetes | 51 (14.0%) |
| Dyslipidemia | 174 (47.9%) |
| Coronary artery disease | 8 (2.2%) |
| Heart failure | 115 (32.4%) |
| Atrial fibrillation | 13 (3.6%) |
| Chronic obstructive pulmonary disease | 18 (5.0%) |
| Smoking | 51 (14.0%) |
| NYHA > III | 28 (7.7%) |
| Systolic blood pressure, bpm | 132.9 ± 19.0 |
| Heart rate, bpm | 80.6 ± 14.6 |
| RA history | |
| RA diagnostic (years) | 11.5 ± 10.1 |
| RF or anti CCP positive, N (%) | 277 (78.0%) |
| Articular erosions, N (%) | 123 (34.6%) |
| DAS28 VS (ESR) | 2.8 ± 1.2 |
| DAS28 VS (CRP) | 2.4 ± 1.1 |
| Medication | |
| ACE inhibitor or ARB, N (%) | 136 (38.3%) |
| Beta-blocker, N (%) | 40 (11.3%) |
| Calcium channel blocker, N (%) | 40 (11.3%) |
| Aldosterone antagonist, N (%) | 2 (0.6%) |
| Loop diuretics, N (%) | 10 (2.8%) |
| Statin, N (%) | 134 (37.7%) |
| Corticosteroids, N (%) | 162 (45.6%) |
| Methotrexate, N (%) | 215 (60.7%) |
| NSAIDs, N (%) | 85 (23.9%) |
| Biological DMARDs, N (%) | 65 (18.3%) |
| Individual DMNARDs | |
| Anti-TNFα | 38 (60.3%) |
| Rituximab | 11 (16.2%) |
| Tocilizumab | 16 (23.5%) |
| Biochemistry | |
| HbA1c, % | 5.6 ± 0.8 |
| LDL cholesterol, mg/dl | 101.0 ± 31.0 |
| Hemoglobin, g/dl | 13.1 ± 1.4 |
| eGFR, ml/min/1.73 m2 | 88.3 ± 20.3 |
| Echocardiogram | |
| LVEF, % | 61.0 ± 7.1 |
| LVEF <50%, N (%) | 17 (5.0%) |
| LVMi, g/m2 | 69.6 ± 21.4 |
| LV hypertrophy, N (%) | 32 (9.0%) |
| LAVi, ml/m2 | 32.4 ± 10.9 |
| LAVi >34 ml/m2, N (%) | 129 (35.7%) |
| E/A ratio | 1.0 ± 0.7 |
| e′ mean, cm/s | 8.9 ± 2.7 |
| Septal e′ <8 cm/s or l ateral e′ <10 cm/s, N (%) | 205 (57.7%) |
| E/e' mean | 9.3 ± 3.9 |
| E/e′ mean >14, N (%) | 30 (8.4%) |
| Peak TR velocity, cm/s (N = 178) | 2.3 ± 0.4 |
| Peak TR velocity > 2.8 cm/s, N (%) (N = 178) | 12 (6.7%) |
| Pulmonary artery systolic pressure, mmHg | 23.7 ± 7.6 |
Values are mean ± SD, n (%) or median (25th−75th percentile).
NYHA, New York Heart Association; RA, rheumatoid arthritis; anti-CCP, anti-citrulline antibody; DAS28 VS (ESR), Disease Activity Score for Rheumatoid Arthritis with Erythrocyte Sedimentation Rate; ACE inhibitor, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; NSAIDs, nonsteroidal anti-inflammatory drugs; DMARDs, disease-modifying anti-rheumatic drugs; HbA1c, glycosylated hemoglobin; LDL, low-density lipoprotein; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; LVMi, left ventricular mass index; LAVi, left atrial volume index; TR, tricuspid regurgitation.